title: A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
abstract: Pharmacogenetics is the search for heritable genetic polymorphisms that influence responses to drug therapy. The most important application of pharmacogenetics is to guide choosing agents with the greatest potential of efficacy and smallest risk of adverse drug reactions. Many studies focusing on drug-gene interactions have been published in recent years, some of which led to adaptation of FDA recommendations, indicating that we are on the verge of the clinical application of genetic information in drug therapy. This systematic review provides a comprehensive overview of the current knowledge on pharmacogenetics of all major drug classes currently used in the treatment of cardiovascular diseases.
authors.affiliation: Department of Cardiology, Leiden University Medical Center, The Netherlands.
authors.forename: Jeffrey J W
authors.initials: JJ
authors.lastname: Verschuren
authors.forename: Stella
authors.initials: S
authors.lastname: Trompet
authors.forename: Judith A M
authors.initials: JA
authors.lastname: Wessels
authors.forename: Henk-Jan
authors.initials: HJ
authors.lastname: Guchelaar
authors.forename: Moniek P M
authors.initials: MP
authors.lastname: de Maat
authors.forename: Maarten L
authors.initials: ML
authors.lastname: Simoons
authors.forename: J Wouter
authors.initials: JW
authors.lastname: Jukema
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001057:Apolipoproteins E / Q000235:genetics; D001241:Aspirin / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D004351:Drug Resistance / Q000235:genetics; D005544:Forecasting; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D016547:Kinesins / Q000235:genetics; D009135:Muscular Diseases / Q000139:chemically induced / Q000235:genetics; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D010597:Pharmacogenetics / Q000458:organization & administration*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011110:Polymorphism, Genetic / Q000235:genetics*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D012084:Renin-Angiotensin System / Q000235:genetics; D012307:Risk Factors
chemical_list: D000317:Adrenergic alpha-Antagonists; D000925:Anticoagulants; D001057:Apolipoproteins E; D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D058921:Purinergic P2Y Receptor Antagonists; D007703:Peptidyl-Dipeptidase A; C526774:KIF6 protein, human; D016547:Kinesins; D001241:Aspirin